Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151105 | 0.93 | MLNR (0.61) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8638021 | 0.93 | MLNR (0.59) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL9146733 | 0.91 | MLNR (0.57) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8640475 | 0.91 | MLNR (0.57) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8640730 | 0.90 | KCNH2 (0.75) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8640368 | 0.89 | MLNR (0.55) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8301500 | 0.88 | MLNR (0.68) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL8638345 | 0.88 | KCNH2 (0.68) | KCNH2 | |
| SCHEMBL8295653 | 0.88 | KCNH2 (0.75) | MLNRCACNA1FNR1I2ABCB11ABCB1 | |
| SCHEMBL9120920 | 0.88 | KCNH2 (0.75) | MLNRCACNA1FNR1I2ABCB11ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-0575430-B1 | PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF ADDICTION TO DRUGS AND SUBSTANCES OF ABUSE | LUNDBECK & CO AS H (DK) | 1998-08-05 | — | — | EP | disclosed |
| EP-0575429-B1 | TREATMENT OF COGNITIVE DISORDERS | LUNDBECK & CO AS H (DK) | 1995-12-06 | — | — | EP | disclosed |
| US-5462948-A | Treatment of addiction to drugs and substances of abuse | H. LUNDBECK A/S (DK) | 1995-10-31 | — | — | US | disclosed |
| US-5444073-A | Administering 1-aryl-3-(4-piperidyl)-indole derivatives | H. LUNDBECK A/S (DK) | 1995-08-22 | — | — | US | disclosed |
| US-5439922-A | Administering dopamine antagonists having reduced side effects | H. LUNDBECK A/S (DK) | 1995-08-08 | — | — | US | disclosed |
| EP-0533824-B1 | PIPERIDYL-SUBSTITUTED INDOLES | LUNDBECK & CO AS H (DK) | 1994-11-09 | — | — | EP | disclosed |
| EP-0575429-A1 | TREATMENT OF COGNITIVE DISORDERS. | LUNDBECK & CO AS H (DK) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992015303-A1 | TREATMENT OF COGNITIVE DISORDERS | H. LUNDBECK A/S (DK) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152573-A1 | BIOORTHOGONAL METHODS AND COMPOUNDS | DDT, DPYD, DNPEP | MLNR 3116/4885CACNA1F 4578/4885NR1I2 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.